JP2019529481A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529481A5
JP2019529481A5 JP2019516972A JP2019516972A JP2019529481A5 JP 2019529481 A5 JP2019529481 A5 JP 2019529481A5 JP 2019516972 A JP2019516972 A JP 2019516972A JP 2019516972 A JP2019516972 A JP 2019516972A JP 2019529481 A5 JP2019529481 A5 JP 2019529481A5
Authority
JP
Japan
Prior art keywords
theta
crystalline form
compound
crystal
starting temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019516972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529481A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/054227 external-priority patent/WO2018064441A1/en
Publication of JP2019529481A publication Critical patent/JP2019529481A/ja
Publication of JP2019529481A5 publication Critical patent/JP2019529481A5/ja
Withdrawn legal-status Critical Current

Links

JP2019516972A 2016-09-30 2017-09-29 胆汁酸誘導体の結晶形態 Withdrawn JP2019529481A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662402813P 2016-09-30 2016-09-30
US62/402,813 2016-09-30
PCT/US2017/054227 WO2018064441A1 (en) 2016-09-30 2017-09-29 Crystalline forms of a bile acid derivative

Publications (2)

Publication Number Publication Date
JP2019529481A JP2019529481A (ja) 2019-10-17
JP2019529481A5 true JP2019529481A5 (enExample) 2020-09-17

Family

ID=61760943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019516972A Withdrawn JP2019529481A (ja) 2016-09-30 2017-09-29 胆汁酸誘導体の結晶形態

Country Status (11)

Country Link
US (1) US20200024299A1 (enExample)
EP (1) EP3518937A4 (enExample)
JP (1) JP2019529481A (enExample)
KR (1) KR20190057108A (enExample)
CN (1) CN109963567A (enExample)
AU (1) AU2017336803A1 (enExample)
BR (1) BR112019006242A2 (enExample)
CA (1) CA3038534A1 (enExample)
IL (1) IL265621A (enExample)
MX (1) MX2019003684A (enExample)
WO (1) WO2018064441A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2040713E (pt) * 2006-06-27 2014-10-13 Intercept Pharmaceuticals Inc Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr
ES2559521T3 (es) * 2006-10-16 2016-02-12 Thesan Pharmaceuticals, Inc. Pirazolil tienopiridinas terapéuticas
WO2009051112A1 (ja) * 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
EP2468762A1 (en) * 2010-11-30 2012-06-27 Dr. Falk Pharma Gmbh Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
NZ734451A (en) * 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
AU2013334122B2 (en) * 2012-10-26 2017-11-02 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives
SG11201503697TA (en) * 2012-11-28 2015-06-29 Intercept Pharmaceuticals Inc Treatment of pulmonary disease
HUP1300504A2 (en) * 2013-08-27 2015-03-30 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sorafenib salts
CN108137643A (zh) * 2015-08-07 2018-06-08 英特塞普特医药品公司 制备胆汁酸及其衍生物的方法
EP3353189A4 (en) * 2015-09-24 2019-06-19 Intercept Pharmaceuticals, Inc. METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF GALLENIC ACID DERIVATIVES

Similar Documents

Publication Publication Date Title
JP2019529481A5 (enExample)
JP4138886B2 (ja) 2−アミノ−4−(4−フルオルベンジルアミノ)−1−エトキシカルボニル−アミノベンゼンの新規変態ならびにその製造法
JP2018531963A5 (enExample)
JP2020511461A5 (enExample)
EP2785701B1 (en) Crystalline form of carbazitaxel and process for preparation thereof
CN103930414B (zh) 7-{(3s,4s)-3-[(环丙基氨基)甲基]-4-氟吡咯烷-1-基}-6-氟-1-(2-氟乙基)-8-甲氧基-4-氧-1,4-二氢喹啉-3-羧酸晶体
JP2014501282A5 (enExample)
JP2011513485A5 (enExample)
JP7473486B2 (ja) Rad1901-2hclの多形形態
JP2010535742A5 (enExample)
JP2013516473A5 (enExample)
JP2019505533A5 (enExample)
JP2022511800A5 (enExample)
RU2015103065A (ru) Кристаллическая форма i дималеата ингибитора тирозинкиназы и способ ее получения
JP2018516883A5 (enExample)
JP2020536893A5 (enExample)
JP2010514725A5 (enExample)
JP2019505532A5 (enExample)
JP2015516425A5 (enExample)
JP2013520488A5 (enExample)
AU2014259029A1 (en) Polymorphic forms of nilotinib hydrochloride
JP2013505234A (ja) 3−(4−アミノ−1−オキソ−1,3−ジヒドロ−イソインドール−2−イル)−ピペリジン−2,6−ジオンの固形体およびその製造方法
JP2012509281A5 (enExample)
JP2016204373A5 (enExample)
JP2005529084A5 (enExample)